TRVI today
$13.72+$0.10 (+0.73%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourLeaning Bullish
15 minSymmetric Triangle
5 minStrong Bullish
Daily trend turns up above $14.77
Key levels
Resistance$16.08
Resistance$14.53
Support$12.79
Support$11.70
Latest news & SEC filings
EarningsTrevi Therapeutics Posts Q3 2026 Results, Gives Business Update
EarningsTrevi Therapeutics holds Q3 2026 earnings call
SEC FilingTrevi Therapeutics, Inc. filed a report on a major company event (Form 8-K)
EarningsTrevi Therapeutics reports Q3 EPS of $(0.13), matching estimates
All TRVI news →About Trevi Therapeutics
Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release form of nalbuphine, for chronic cough. Its programs target cough in idiopathic pulmonary fibrosis, other interstitial lung diseases, and refractory chronic cough. The company holds worldwide commercial rights to Haduvio.
Based on the company's 10-K filed Mar 17, 2026.
Nasdaq · Healthcare
Trevi Therapeutics, Inc. (TRVI)
What Is the Price Target for TRVI?
SEPT Low Target
$21.00
SEPT Mid Target
$28.00
SEPT High Target
$36.00
Analyst Consensus
$28.00
Is TRVI a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TRVI.
Start Free Trial →Is TRVI Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$22.26
12
Moat Score
NONE
4/9
Piotroski Score
99.5
Altman Z-Score
What Is Smart Money Doing with TRVI?
Insider Signal
NEUTRAL
0 buys / 3 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Heffernan Michael Thomas | director | Buy | 18,421 | $56K | Sep 15, 2026 |
| Heffernan Michael Thomas | director | Sale | 18,321 | $276K | Sep 15, 2026 |
| Heffernan Michael Thomas | director | Sale | 100 | $2K | Sep 15, 2026 |
| Heffernan Michael Thomas | director | Buy | 21,052 | $70K | Sep 15, 2026 |
| Heffernan Michael Thomas | director | Sale | 20,952 | $316K | Sep 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TRVI Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
31.91%
FCF Growth YoY
-9.9%
Revenue Trend
UNKNOWN
Dark Pool Trades for TRVI
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for TRVI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:25:09 | $13.74 | 2,000 | $$27K | BUY |
| 20:15:53 | $13.71 | 1,755 | $$24K | MIDPOINT |
| 19:43:05 | $13.70 | 1,000 | $$14K | SELL |
| 19:00:06 | $13.67 | 2,663 | $$36K | SELL |
| 17:48:08 | $13.62 | 3,000 | $$41K | SELL |
5 dark pool trades shown · $$143K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About TRVI
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for TRVI. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup -- $TRVI (Trevi Therapeutics, Inc.) Price: $17.93 | Zone: $14.15 to $19.26 Conviction: HIGH | Analyst upside: +23.6% Near resistance (74% of range) — breakout watch. Earnings: EPS_BEAT. E...
Join 3,500+ traders discussing TRVI in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Trevi Therapeutics, Inc. (TRVI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TRVI — frequently asked questions
What is TRVI stock price today?
Trevi Therapeutics, Inc. (TRVI) is at $13.72, up 0.73% (+$0.10) at the Nov 13, 2026 close.
Why is TRVI stock moving today?
Latest TRVI news — Nov 9, 2026: Trevi Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 9, 2026: Trevi Therapeutics holds Q3 2026 earnings call
What is the TRVI price target?
The average analyst price target for TRVI is $28.00, ranging from $21 to $36, based on 9 analysts. Latest: Jones Trading maintains on Aug 14, 2026.
What do analysts rate TRVI?
Analyst ratings for TRVI: 11 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did TRVI beat earnings?
TRVI last reported on Aug 6, 2026: EPS -$0.11 vs -$0.11 expected — a miss of 0.5%.
Does TRVI pay a dividend?
TRVI does not currently pay a dividend.
What are TRVI support and resistance levels?
Support: $12.79, $11.70, $10.25. Resistance: $14.53, $16.08, $17.32.
What are insiders doing with TRVI?
Insider activity: NEUTRAL, 0 buys and 3 sells in the last 90 days.
What is the latest news on TRVI?
Nov 9, 2026: Trevi Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 9, 2026: Trevi Therapeutics holds Q3 2026 earnings call · Nov 9, 2026: Trevi Therapeutics, Inc. filed a report on a major company event (Form 8-K)